Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Hanchae | - |
dc.contributor.author | Jung, Inseong | - |
dc.contributor.author | Ju, Hyunji | - |
dc.contributor.author | Baek, Moon-Chang | - |
dc.contributor.author | Yea, Kyungmoo | - |
dc.date.accessioned | 2023-07-12T14:10:20Z | - |
dc.date.available | 2023-07-12T14:10:20Z | - |
dc.date.created | 2023-07-06 | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 1043-4666 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11750/46136 | - |
dc.description.abstract | Lung cancer is a common and highly malignant tumor. Although lung cancer treatments continue to advance, conventional therapies are limited and the response rate of patients to immuno-oncology drugs is low. This phenomenon raises an urgent need to develop effective therapeutic strategies for lung cancer. In this study, we genetically modified human primary CD8+ T cells and obtained antitumor extracellular vesicles (EVs) from them. The engineered EVs, containing interlekin-2 and the anti-epidermal growth factor receptor (EGFR) antibody cetuximab on their surfaces, exhibited direct cytotoxicity against A549 human lung cancer cells and increased cancer cell susceptibility to human peripheral blood mononuclear cell-mediated cytotoxicity. In addition, the engineered EVs specifically targeted the lung cancer cells in an EGFR-dependent manner. Taken together, these findings show that surface engineering of cytokines and antibodies on CD8+ T cell-derived EVs not only enhances their antitumor effects but also confers target specificity, suggesting a potential of modifying the immune cell-derived EVs in cancer treatment. © 2023 Elsevier Ltd | - |
dc.language | English | - |
dc.publisher | Academic Press | - |
dc.title | Engineered CD8+ T cell-derived extracellular vesicles induce enhanced anti-cancer efficacy and targeting to lung cancer cells | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.cyto.2023.156249 | - |
dc.identifier.wosid | 001015627500001 | - |
dc.identifier.scopusid | 2-s2.0-85161279300 | - |
dc.identifier.bibliographicCitation | Cytokine, v.169, pp.156249 | - |
dc.description.isOpenAccess | FALSE | - |
dc.subject.keywordAuthor | Extracellular vesicles | - |
dc.subject.keywordAuthor | Interleukin-2 | - |
dc.subject.keywordAuthor | Cetuximab | - |
dc.subject.keywordAuthor | Cytotoxic T cell | - |
dc.subject.keywordAuthor | Lung cancer | - |
dc.subject.keywordPlus | HIGH-DOSE INTERLEUKIN-2 | - |
dc.subject.keywordPlus | ANTITUMOR RESPONSE | - |
dc.subject.keywordPlus | EXOSOMES | - |
dc.subject.keywordPlus | CHALLENGES | - |
dc.subject.keywordPlus | IMMUNITY | - |
dc.subject.keywordPlus | CTLS | - |
dc.citation.startPage | 156249 | - |
dc.citation.title | Cytokine | - |
dc.citation.volume | 169 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology; Cell Biology; Immunology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology; Cell Biology; Immunology | - |
dc.type.docType | Article | - |
There are no files associated with this item.